Abstract | AIM: METHODS: An audit was performed on children aged 16 years and younger presenting with fever and neutropenia who were managed with empirical single-agent cefepime. The patients were analysed for clinical outcome, documented infections and side-effects of the study drug. Success was defined as clinical improvement without treatment modification. Death or any change to the empirical antibiotic was considered as failure. RESULTS: In this study 79 children (median age 5.2 years) with 133 episodes of febrile neutropenia were prospectively studied between August 2004 and August 2005. A microbiologically documented infection was seen in 26 episodes. The success rate of cefepime monotherapy was 60%. The rate of survival through neutropenia (with or without modification) was 98%. No significant adverse effects were seen. CONCLUSION:
|
Authors | Hany Ariffin, Chong Lee Ai, Chan Lee Lee, Wan Ariffin Abdullah |
Journal | Journal of paediatrics and child health
(J Paediatr Child Health)
Vol. 42
Issue 12
Pg. 781-4
(Dec 2006)
ISSN: 1034-4810 [Print] Australia |
PMID | 17096713
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Anti-Bacterial Agents
- Cephalosporins
- Vancomycin
- Cefepime
|
Topics |
- Adolescent
- Anti-Bacterial Agents
(therapeutic use)
- Cefepime
- Cephalosporins
(therapeutic use)
- Child
- Child, Preschool
- Female
- Fever
(drug therapy, etiology)
- Humans
- Infant
- Malaysia
- Male
- Neoplasms
(complications)
- Neutropenia
(drug therapy, etiology)
- Prospective Studies
- Treatment Outcome
- Vancomycin
(therapeutic use)
|